OSCROscar Health, Inc.

NYSE hioscar.com


$ 21.93 $ 0.31 (1.43 %)    

Monday, 16-Sep-2024 15:59:59 EDT
QQQ $ 473.14 $ -2.10 (-0.44 %)
DIA $ 417.33 $ 2.44 (0.59 %)
SPY $ 562.48 $ 0.83 (0.15 %)
TLT $ 101.29 $ 0.92 (0.92 %)
GLD $ 238.61 $ -0.02 (-0.01 %)
$ 21.92
$ 21.72
$ 21.90 x 100
-- x --
$ 21.62 - $ 22.27
$ 4.72 - $ 23.44
2,540,431
na
5.3B
$ 1.92
$ 292.21
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 02-15-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 02-24-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-11-2022 03-31-2022 10-Q
11 02-25-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-13-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 piper-sandler-reiterates-overweight-on-oscar-health-maintains-28-price-target

Piper Sandler analyst Jessica Tassan reiterates Oscar Health (NYSE:OSCR) with a Overweight and maintains $28 price target.

 piper-sandler-maintains-overweight-on-oscar-health-raises-price-target-to-28

Piper Sandler analyst Jessica Tassan maintains Oscar Health (NYSE:OSCR) with a Overweight and raises the price target from $...

 oscar-health-raises-fy24-revenue-forecast-from-83b---84b-to-90b---91b-est-8604b

Adjusted EBITDA to be in the $160 million to $210 million range, $35 million higher than the prior range of $125 million to $17...

 oscar-health-q2-2024-gaap-eps-020-beats-016-estimate-sales-2219b-beat-2155b-estimate

Oscar Health (NYSE:OSCR) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.16 by 2...

 piper-sandler-maintains-overweight-on-oscar-health-maintains-25-price-target

Piper Sandler analyst Jessica Tassan maintains Oscar Health (NYSE:OSCR) with a Overweight and maintains $25 price target.

 expert-ratings-for-oscar-health
Expert Ratings For Oscar Health
06/26/2024 13:01:18

 piper-sandler-initiates-coverage-on-oscar-health-with-overweight-rating-announces-price-target-of-25

Piper Sandler analyst Jessica Tassan initiates coverage on Oscar Health (NYSE:OSCR) with a Overweight rating and announces P...

 wells-fargo-maintains-overweight-on-oscar-health-raises-price-target-to-27

Wells Fargo analyst Stephen Baxter maintains Oscar Health (NYSE:OSCR) with a Overweight and raises the price target from $24...

 b-of-a-securities-downgrades-oscar-health-to-neutral-lowers-price-target-to-21

B of A Securities analyst Adam Ron downgrades Oscar Health (NYSE:OSCR) from Buy to Neutral and lowers the price target from ...

 baird-initiates-coverage-on-oscar-health-with-outperform-rating-announces-price-target-of-28

Baird analyst Michael Ha initiates coverage on Oscar Health (NYSE:OSCR) with a Outperform rating and announces Price Target ...

 b-of-a-securities-maintains-buy-on-oscar-health-raises-price-target-to-25

B of A Securities analyst Adam Ron maintains Oscar Health (NYSE:OSCR) with a Buy and raises the price target from $22 to $25.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION